Icon, a global provider of outsourced development services, has launched a new medical imaging solution tailored to the unique requirements of early phase trials.

This new solution incorporates streamlined processes and procedures to maximize the information collected from image data and to ensure that this information is processed rapidly in line with the shorter timelines and requirements of early-phase research. Enhanced decision making is then enabled by MIRA, Icon’s image management system, which standardizes data from all imaging formats and allows for centralized analysis and interpretation of data.

Driving this innovation is a team of scientific and regulatory experts with deep imaging and early-phase experience to help sponsors make critical decisions about their compounds faster.

“PET, volumetrics, advanced CT and MRI are increasingly being used in early phase research which has created a demand for more tailored imaging solutions for early phase trials,” said Ted Gastineau, president of Icon Medical Imaging. “We have developed a unique and cost-effective solution that provides true insight to the data generated from imaging technologies and helps clients decide earlier about the future success of a drug.”

Icon Medical Imaging’s early phase group will be led by Dr. James Conklin, senior vice president of medical and scientific affairs, and Dr. Valerie Treyer, director of medical and scientific affairs, who together bring over 45 years of experience in the management of medical image data used in clinical trials. The group will work closely with Icon Development Solutions, which provides a full range of early-phase services, including clinical pharmacology, bioanalytical, PK/PD modelling and simulation and clinical pharmacodynamic models for early indications of drug efficacy.